NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Mattila, Henna ^a   Schindler, Martin ^a   Isotalo, Jarkko ^a   Ikonen, Tarja ^a   Vihinen, Mauno ^b   Oja, Hannu ^b   Tammela, Teuvo L J ^c   Wahlfors, Tiina ^a   Schleutker, Johanna ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MAGEC1 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE LOCATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETIC SELECTION; GENETIC VARIABILITY; HPCX1 GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA ANTIGEN FAMILY C 1 GENE; MICROARRAY ANALYSIS; MUTATIONAL ANALYSIS; NONSENSE MEDIATED MRNA DECAY; PATHOGENESIS; PEDIGREE ANALYSIS; PROSTATE CANCER; RNA ANALYSIS; SEQUENCE ANALYSIS; START CODON; TUMOR GENE; UPREGULATION; VALIDATION PROCESS; CANCER STAGING; CELL LINE; DNA MICROARRAY; FAMILY HEALTH; GENETICS; GENOTYPE; MIDDLE AGED; MUTATION; PATHOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; X CHROMOSOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CELL LINE, TRANSFORMED; CHROMOSOMES, HUMAN, X; FAMILY HEALTH; FEMALE; GENE EXPRESSION PROFILING; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; NEOPLASM STAGING; NONSENSE MEDIATED MRNA DECAY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79960893958     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-327     Document Type: Article

References (38)

1. Finnish Cancer Registry: Cancer statistics 2008, Finnish Cancer Registry: Cancer statistics., http://www.cancerregistry.fi
2. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000, 343:78-85. 10.1056/NEJM200007133430201, 10891514.
3. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004, 13(Spec No 1):R103-21.
4. Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, Ewing C, Wilkens E, Bujnovszky P, Bova GS, Walsh P, Isaacs W, Schleutker J, Matikainen M, Tammela T, Visakorpi T, Kallioniemi OP, Berry R, Schaid D, French A, McDonnell S, Schroeder J, Blute M, Thibodeau S, Grönberg H, Emanuelsson M, Damber JE, Bergh A, Jonsson BA, Smith J, et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 1998, 20:175-179. 10.1038/2477, 9771711.
5. Schleutker J, Matikainen M, Smith J, Koivisto P, Baffoe-Bonnie A, Kainu T, Gillanders E, Sankila R, Pukkala E, Carpten J, Stephan D, Tammela T, Brownstein M, Bailey-Wilson J, Trent J, Kallioniemi OP. A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: frequent HPCX linkage in families with late-onset disease. Clin Cancer Res 2000, 6:4810-4815.
6. Baffoe-Bonnie AB, Smith JR, Stephan DA, Schleutker J, Carpten JD, Kainu T, Gillanders EM, Matikainen M, Teslovich TM, Tammela T, Sood R, Balshem AM, Scarborough SD, Xu J, Isaacs WB, Trent JM, Kallioniemi OP, Bailey-Wilson JE. A major locus for hereditary prostate cancer in Finland: localization by linkage disequilibrium of a haplotype in the HPCX region. Hum Genet 2005, 117:307-316. 10.1007/s00439-005-1306-z, 15906096.
7. Stephan DA, Howell GR, Teslovich TM, Coffey AJ, Smith L, Bailey-Wilson JE, Malechek L, Gildea D, Smith JR, Gillanders EM, Schleutker J, Hu P, Steingruber HE, Dhami P, Robbins CM, Makalowska I, Carpten JD, Sood R, Mumm S, Reinbold R, Bonner TI, Baffoe-Bonnie A, Bubendorf L, Heiskanen M, Kallioniemi OP, Baxevanis AD, Joseph SS, Zucchi I, Burk RD, Isaacs W, et al. Physical and transcript map of the hereditary prostate cancer region at Xq27. Genomics 2002, 79:41-50. 10.1006/geno.2001.6681, 11827456.
8. Kouprina N, Pavlicek A, Noskov VN, Solomon G, Otstot J, Isaacs W, Carpten JD, Trent JM, Schleutker J, Barrett JC, Jurka J, Larionov V. Dynamic structure of the SPANX gene cluster mapped to the prostate cancer susceptibility locus HPCX at Xq27. Genome Res 2005, 15:1477-1486. 10.1101/gr.4212705, 1310635, 16251457.
9. Kouprina N, Noskov VN, Solomon G, Otstot J, Isaacs W, Xu J, Schleutker J, Larionov V. Mutational analysis of SPANX genes in families with X-linked prostate cancer. Prostate 2007, 67:820-828. 10.1002/pros.20561, 17373721.
10. Culbertson MR. RNA surveillance. Unforeseen consequences for gene expression, inherited genetic disorders and cancer. Trends Genet 1999, 15:74-80. 10.1016/S0168-9525(98)01658-8, 10098411.
11. Noensie EN, Dietz HC. A strategy for disease gene identification through nonsense-mediated mRNA decay inhibition. Nat Biotechnol 2001, 19:434-439. 10.1038/88099, 11329012.
12. Ionov Y, Nowak N, Perucho M, Markowitz S, Cowell JK. Manipulation of nonsense mediated decay identifies gene mutations in colon cancer cells with microsatellite instability. Oncogene 2004, 23:639-645. 10.1038/sj.onc.1207178, 14737099.
13. Fabbri M, Croce CM, Calin GA. MicroRNAs. Cancer J 2008, 14:1-6. 10.1097/PPO.0b013e318164145e, 18303474.
14. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, Yfantis HG, Stephens RM, Croce CM. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008, 68:6162-6170. 10.1158/0008-5472.CAN-08-0144, 2597340, 18676839.
15. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008, 27:1788-1793. 10.1038/sj.onc.1210809, 17891175.
16. Baskerville S, Bartel DP. Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA 2005, 11:241-247. 10.1261/rna.7240905, 1370713, 15701730.
17. Cropp CD, Simpson CL, Wahlfors T, Ha N, George A, Jones MS, Harper U, Ponciano-Jackson D, Green TA, Tammela TL, Bailey-Wilson J, Schleutker J. Genome-wide linkage scan for prostate cancer susceptibility in Finland: Evidence for a novel locus on 2q37.2 and confirmation of signal on 17q21-q22. Int J Cancer 2011,
18. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A, . ERSPC Investigators Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-1328. 10.1056/NEJMoa0810084, 19297566, ERSPC Investigators.
19. Enright AJ, John B, Gaul U, Tuschl T, Sander C, Marks DS. MicroRNA targets in Drosophila. Genome Biol 2003, 5:R1. 10.1186/gb-2003-5-1-r1, 395733, 14709173.
20. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucleic Acids Res 2008, 36:D154-8. 10.1093/nar/gkn221, 2238936, 17991681.
21. Mendell JT, Sharifi NA, Meyers JL, Martinez-Murillo F, Dietz HC. Nonsense surveillance regulates expression of diverse classes of mammalian transcripts and mutes genomic noise. Nat Genet 2004, 36:1073-1078. 10.1038/ng1429, 15448691.
22. Pakkanen S, Baffoe-Bonnie AB, Matikainen MP, Koivisto PA, Tammela TL, Deshmukh S, Ou L, Bailey-Wilson JE, Schleutker J. Segregation analysis of 1,546 prostate cancer families in Finland shows recessive inheritance. Hum Genet 2007, 121:257-267. 10.1007/s00439-006-0310-2, 1945246, 17203302.
23. Huusko P, Ponciano-Jackson D, Wolf M, Kiefer JA, Azorsa DO, Tuzmen S, Weaver D, Robbins C, Moses T, Allinen M, Hautaniemi S, Chen Y, Elkahloun A, Basik M, Bova GS, Bubendorf L, Lugli A, Sauter G, Schleutker J, Ozcelik H, Elowe S, Pawson T, Trent JM, Carpten JD, Kallioniemi OP, Mousses S. Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet 2004, 36:979-983. 10.1038/ng1408, 15300251.
24. Bloethner S, Mould A, Stark M, Hayward NK. Identification of ARHGEF17, DENND2D, FGFR3, and RB1 mutations in melanoma by inhibition of nonsense-mediated mRNA decay. Genes Chromosomes Cancer 2008, 47:1076-1085. 10.1002/gcc.20598, 18677770.
25. Ivanov I, Lo KC, Hawthorn L, Cowell JK, Ionov Y. Identifying candidate colon cancer tumor suppressor genes using inhibition of nonsense-mediated mRNA decay in colon cancer cells. Oncogene 2007, 26:2873-2884. 10.1038/sj.onc.1210098, 17086209.
26. Rossi MR, Hawthorn L, Platt J, Burkhardt T, Cowell JK, Ionov Y. Identification of inactivating mutations in the JAK1, SYNJ2, and CLPTM1 genes in prostate cancer cells using inhibition of nonsense-mediated decay and microarray analysis. Cancer Genet Cytogenet 2005, 161:97-103. 10.1016/j.cancergencyto.2005.02.006, 16102578.
27. Cui J, Staples MP, Hopper JL, English DR, McCredie MR, Giles GG. Segregation analyses of 1,476 population-based Australian families affected by prostate cancer. Am J Hum Genet 2001, 68:1207-1218. 10.1086/320114, 1226101, 11309686.
28. Lucas S, De Smet C, Arden KC, Viars CS, Lethé B, Lurquin C, Boon T. Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. Cancer Res 1998, 58:743-752.
29. Zmuda JM, Cauley JA, Ferrell RE. Molecular epidemiology of vitamin D receptor gene variants. Epidemiol Rev 2000, 22:203-217.
30. Wolf M, Edgren H, Muggerud A, Kilpinen S, Huusko P, Sorlie T, Mousses S, Kallioniemi O. NMD microarray analysis for rapid genome-wide screen of mutated genes in cancer. Cell Oncol 2005, 27:169-173.
31. Sie L, Loong S, Tan EK. Utility of lymphoblastoid cell lines. J Neurosci Res 2009, 87:1953-9. 10.1002/jnr.22000, 19224581.
32. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R, Haqq C. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 2006, 5:24. 10.1186/1476-4598-5-24, 1563474, 16784538.
33. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007, 67:6130-6135. 10.1158/0008-5472.CAN-07-0533, 17616669.
34. deVere White RW, Vinall RL, Tepper CG, Shi XB. MicroRNAs and their potential for translation in prostate cancer. Urol Oncol 2009, 27:307-311. 10.1016/j.urolonc.2009.01.004, 2761743, 19414119.
35. Lutter D, Marr C, Krumsiek J, Lang EW, Theis FJ. Intronic microRNAs support their host genes by mediating synergistic and antagonistic regulatory effects. BMC Genomics 2010, 11:224. 10.1186/1471-2164-11-224, 2865499, 20370903.
36. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008, 105:10513-18. 10.1073/pnas.0804549105, 2492472, 18663219.
37. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Harris AL. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008, 141:672-675. 10.1111/j.1365-2141.2008.07077.x, 18318758.
38. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 10:997-1006.